Verastegui E - Search Results

1

A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma.

Dueñas-Gonzalez A, Verastegui E, Lopez-Graniel C, Gonzalez A, Mota A, Barrera-Franco JL, Meneses A, Chanona J, de la Garza J, Chavez-Blanco A, Hadden JW. Dueñas-Gonzalez A, et al. Among authors: verastegui e. Int Immunopharmacol. 2002 Jun;2(7):1007-16. doi: 10.1016/s1567-5769(02)00048-6. Int Immunopharmacol. 2002. PMID: 12188025

2

Long-term immune dysfunction after radiotherapy to the head and neck area.

Verastegui EL, Morales RB, Barrera-Franco JL, Poitevin AC, Hadden J. Verastegui EL, et al. Int Immunopharmacol. 2003 Aug;3(8):1093-1104. doi: 10.1016/S1567-5769(03)00013-4. Int Immunopharmacol. 2003. PMID: 12860166 Clinical Trial.

3

Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.

Meneses A, Verastegui E, Barrera JL, de la Garza J, Hadden JW. Meneses A, et al. Among authors: verastegui e. Int Immunopharmacol. 2003 Aug;3(8):1083-91. doi: 10.1016/S1567-5769(03)00017-1. Int Immunopharmacol. 2003. PMID: 12860165

4

A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.

Verastegui E, Barrera JL, Zinser J, Del Rio R, Meneses A, De La Garza J, Hadden JW. Verastegui E, et al. Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):619-27. doi: 10.1016/s0192-0561(97)00059-3. Int J Immunopharmacol. 1997. PMID: 9669202 Clinical Trial.

5

A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.

Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E. Hadden J, et al. Among authors: verastegui e. Int Immunopharmacol. 2003 Aug;3(8):1073-81. doi: 10.1016/S1567-5769(03)00029-8. Int Immunopharmacol. 2003. PMID: 12860164 Clinical Trial.

6

Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.

Meneses A, Verastegui E, Barrera JL, Zinser J, de la Garza J, Hadden JW. Meneses A, et al. Among authors: verastegui e. Arch Pathol Lab Med. 1998 May;122(5):447-54. Arch Pathol Lab Med. 1998. PMID: 9593347 Clinical Trial.

7

Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.

Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Barrera JL, et al. Among authors: verastegui e. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51. doi: 10.1001/archotol.126.3.345. Arch Otolaryngol Head Neck Surg. 2000. PMID: 10722007 Clinical Trial.

8

IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans.

Hadden JW, Verastegui E, Hadden E. Hadden JW, et al. Among authors: verastegui e. Ann N Y Acad Sci. 2007 Sep;1112:245-55. doi: 10.1196/annals.1415.032. Epub 2007 Jun 28. Ann N Y Acad Sci. 2007. PMID: 17600288

9

Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck.

Verastegui E, Morales R, Barrera JL, Müeller A, Guzman B, Meneses A, Alfaro G. Verastegui E, et al. Clin Immunol. 2002 Jan;102(1):37-47. doi: 10.1006/clim.2001.5130. Clin Immunol. 2002. PMID: 11781066

10

Non-Hodgkin's lymphomas in Mexico. A clinicopathological and molecular analysis.

Ortega V, Verastegui E, Flores G, Meneses A, Ocadiz R, Alfaro G. Ortega V, et al. Among authors: verastegui e. Leuk Lymphoma. 1998 Nov;31(5-6):575-82. doi: 10.3109/10428199809057617. Leuk Lymphoma. 1998. PMID: 9922048

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters